Johnson & Johnson Reports Lasting Success for Once-Daily Psoriasis Pill
Beerse, Saturday 28 March 2026
Johnson & Johnson’s pioneering once-daily psoriasis pill demonstrated lasting 52-week effectiveness, achieving completely clear skin in nearly 60% of adolescent patients during late-stage clinical trials.
Clinical Triumphs and Trial Specifics
On 28 March 2026, at the American Academy of Dermatology (AAD) Annual Meeting, comprehensive one-year data for the drug Icotyde (icotrokinra) was unveiled to the medical community [2]. The treatment, the first and only oral peptide designed to specifically target and block the IL-23 receptor, has shown remarkable efficacy in treating plaque psoriasis, a chronic autoimmune condition that accelerates the growth cycle of skin cells [GPT]. Across multiple Phase 3 trials, including the ICONIC-ADVANCE 1 and 2, and ICONIC-LEAD studies, the drug demonstrated significant clinical milestones [2][3]. In the ADVANCE 1 and 2 trials, the proportion of adult patients achieving completely clear skin—measured as a Psoriasis Area and Severity Index (PASI) 100 score—rose steadily between Week 24 and Week 52 [3]. Specifically, rates increased from 41 percent to 49 percent in the ADVANCE 1 trial, and from 33 percent to 48 percent in the ADVANCE 2 trial [3]. Furthermore, patients who transitioned from a placebo to Icotyde at the 16-week mark achieved comparable skin clearance rates of 50 percent and 43 percent, respectively, by the end of the 52-week period [3].
A Strategic Partnership from Lab to Market
The commercialisation of Icotyde is the culmination of a long-standing collaboration between Protagonist Therapeutics and Janssen Biotech, Inc., a subsidiary of Johnson & Johnson, which began in 2017 [2]. Under this agreement, Johnson & Johnson handles the commercial activities for the drug, which is now approved in the United States for both adults and paediatric patients aged 12 and older who weigh at least 40 kilogrammes [2]. This successful lab-to-market transition highlights the formidable operational scale of Johnson & Johnson, a corporate giant that generates 64.1 percent of its net sales from pharmaceutical products and operates 63 manufacturing facilities globally, including 22 in Europe and 22 in the United States [1]. The United States remains a crucial market for the company, accounting for 57.1 percent of its total net sales [1].
Market Implications and Financial Outlook
The positive clinical results arrive at a time of robust financial health for Johnson & Johnson. As of 27 March 2026, the company’s stock closed at 240.42 USD, reflecting a slight increase of 0.46 percent, and bringing its total market capitalisation to an immense 315,282.47 million USD [5]. This valuation significantly outpaces European competitors like Sanofi, which holds a market capitalisation of 100,009.23 million USD [5]. The pharmaceutical giant’s recent quarterly results have exceeded market expectations, driven largely by increased sales in prescription drugs and medical devices that have offset weaknesses in other areas, despite recent cost-cutting staff reductions [5]. Moreover, the company boasts a deeply entrenched market position, with over 75 percent of its sales derived from products holding the number one or number two global market share positions [4].